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Introduction
Antimuscarinic agents are an important treatment for overactive bladder (OAB), acting to increase bladder capacity and reduce urgency during the storage phase (Finney et al., 2006) , but can cause various adverse effects such as dry mouth, constipation, blurred vision, and cognitive impairment (Colli et al., 2007) . Both the therapeutic and adverse effects of these agents are mediated via the blockade of muscarinic receptors in the bladder and in non-target tissues, respectively.
Imidafenacin is a potent antagonist of M 1 and M 3 muscarinic receptors that is used to treat OAB (Homma et al., 2008a and 2009) . Clinical studies have shown that imidafenacin is safe, efficacious, and tolerable for controlling the symptoms of OAB, even as long-term therapy (Homma and Yamaguchi, 2008b; Ohno et al., 2008; Zaitsu et al., 2011; Kadekawa et al., 2012) . Sakakibara et al. (2014) reported that imidafenacin may be used safely to treat OAB in cognitively vulnerable patients. According to a recent systematic review and meta-analysis performed by Huang et al. (2015) , imidafenacin is better tolerated than propiverine or solifenacin based on the incidence of dry mouth and constipation. Pharmacological studies have revealed significant selectivity of imidafenacin for muscarinic receptors in the bladder over those in the salivary gland or brain (Kobayashi et al., 2007a, and 2007b; Yamazaki et al., 2011) . We previously demonstrated that imidafenacin binds with a high affinity to muscarinic receptors in human bladder mucosa and detrusor muscle (Seki et al., 2011) . Also, after low-dose oral administration of imidafenacin to rats, its binding showed a longer duration to muscarinic receptors in the bladder than to receptors in other tissues such as the salivary gland (Yamada et al., 2011) , suggesting preferential binding of bladder muscarinic receptors by this revealed that imidafenacin reached a higher concentration in the bladder than in the serum or submaxillary gland after oral administration (Yamada et al., 2011) . Pharmacologically relevant concentrations of the unchanged drug or active metabolites are excreted in the urine by humans receiving clinical doses of imidafenacin (Masuda et al., 2007) and other antimuscarinic agents (Krauwinkel et al., 2005; Cyong et al., 2006; Ellsworth, 2009; Malhotra et al., 2009 ). These reports suggested a possible contribution of urinary imidafenacin to the pharmacological effects of this drug on the bladder.
[ 3 H]imidafenacin with a high specific activity is a selective radioligand that has been used to label muscarinic receptors in the human bladder and parotid gland (Yoshida et al., 2014 )., and it shows a high affinity for muscarinic receptors in the M 1 and M 3 dominant tissues of rats (Kuraoka et al., in press ). The basis of the in vivo pharmacology of imidafenacin is that its antagonistic effects result from receptor occupancy, which may be determined by an in vivo radioligand-receptor binding assay (Yoshida et al., 2010a) homogenizer (Nition, Tokyo, Japan). Particulate-bound radioactivity was determined by rapid filtration of 0.5 mL of tissue homogenate through a Whatman CF/C filter, followed by washing with 1 mL of ice-cold buffer. After addition of scintillation fluid, radioactivity in the plasma and the tissue particulate fraction was measured by using a liquid scintillation counter. was estimated by converting raw counts to Bq (1 Bq=60 dpm).
Effects of bilateral ureteral ligation on total radioactivity and specific binding of (Fig. 1) , and was highest in the submaxillary gland, followed by the bladder, colon, and heart. At 30 min after injection, gland, heart, colon, and lung, after which it decreased significantly over time. Binding to the particulate fraction of lung tissue was only observed at 10 min, and was it negligible in the particulate fraction of the cerebral cortex. In each tissue, the time course of specific [ 3 H]imidafenacin binding appeared to be parallel to that of total radioactivity ( Fig. 2A) . Figure 4 shows the changes of total radioactivity in the urine over time and specific (Fig. 1) . There was also a significant difference between the bladder and other tissues with regard to the time course of changes in the total radioactivity and specific binding of 
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